<p>Supplementary Table 1: Adjusted odds ratios for the association between IBD therapy and the risk of developing cancer, stratified by the primary recorded extra-intestinal cancer types.</p><p>Ever vs. Never Use of Corticosteroids Ever vs. Ever vs. Never Use of Ever vs. Never Use of AORa (95% CI) Never Immunosuppressants Antibiotics Use of AORa (95% CI) AORa(95% CI) Aminos alicylate s AORa(9 Cancer Site Cases 5% CI) Breast 74 0.79 1.07 (0.58-1.99) (0.39- 0.63 (0.27-1.51) 1.16 (0.56-2.41) 1.60) Lung 52 0.53 1.26 (0.59-2.72) (0.22- 1.03 (0.37-2.85) 1.20 (0.52-2.72) 1.27) Prostate 55 0.32 1.11 (0.52-2.34) (0.13- 1.42 (0.51-3.94) 0.96 (0.40-2.28) 0.80) Lymphoma/Leukemi 40 0.84 a 1.51 (0.59-3.89) (0.31- 1.71 (0.49-5.95) 1.15 (0.43-2.25) 2.25) a multivariable model adjusted for smoking status (non-smoker, current, former, missing), alcohol use (non, current, former, missing), number of GP visits in the year before index date (based on diagnoses), IBD duration, number of IBD symptoms (i.e. diarrhoea, constipation, abdominal pain, blood in stools or intestinal bleeding, anaemia, anal fistula/fissure, weight loss, and anorexia) during the 24 months prior to the index date (as a proxy for severity), and concurrent use of other IBD therapies. A history of pneumonia also included in the lung cancer model </p>